Works matching IS 15272729 AND DT 2022 AND VI 23 AND IP 3

Results: 10

Additive Processing of a X22CrMoV12-1 Steel: Structure, Properties and Product.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 283, doi. 10.1007/s41403-020-00191-x

By:

Mathias, Snehith;
Srinivasan, Dheepa;
Setty, Raghavendra;
Jayaprakash, K. N.;
Ahmed, Saem;
Banerjee, Dipankar

Publication type:

Article

Novel Aeroelastic Approaches for Transonic Flutter and Buffet Clearance of Aerospace Vehicles.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 243, doi. 10.1007/s41403-020-00190-y

By:

Raja, S.

Publication type:

Article

Development of Turbopump Systems for Cryogenic and Semicryogenic Propulsion Systems of ISRO.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 229, doi. 10.1007/s41403-020-00189-5

By:

Suresh, M. S.

Publication type:

Article

Engineering/Technology Talent Development on the College Campus.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 219, doi. 10.1007/s41403-020-00188-6

By:

Ravikumar, C. P.

Publication type:

Article

Identification of a novel cancer microbiome signature for predicting prognosis of human breast cancer patients.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 597, doi. 10.1007/s12094-021-02725-3

By:

Mao, A. W.;
Barck, H.;
Young, J.;
Paley, A.;
Mao, J. -H.;
Chang, H.

Publication type:

Article

Thanks to reviewers 2021.

Published in:: Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 605, doi. 10.1007/s12094-022-02789-9
Publication type:: Article

High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years—single institution experience.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 578, doi. 10.1007/s12094-021-02718-2

By:

Membrive Conejo, I.;
Pera Cegarra, O.;
Foro Arnalot, P.;
Reig Castillejo, A.;
Rodríguez de Dios, N.;
Sanz Latiesas, X.;
Deza, G.;
Quera Jordana, J.;
Fernandez-Velilla Cepria, E.;
Martínez Moñino, A.;
Liu Cheng, F.;
Algara López, M.

Publication type:

Article

PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 586, doi. 10.1007/s12094-021-02723-5

By:

Chen, H.;
Liu, H.;
Ai, J.;
Du, X.;
Sun, Y.;
Xiao, S.

Publication type:

Article

Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 568, doi. 10.1007/s12094-021-02717-3

By:

Ueki, H.;
Hinata, N.;
Kitagawa, K.;
Hara, T.;
Terakawa, T.;
Furukawa, J.;
Harada, K.;
Nakano, Y.;
Komatsu, M.;
Fujisawa, M.;
Shirakawa, T.

Publication type:

Article

Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain.

Published in:

Current Treatment Options in Oncology, 2022, v. 23, n. 3, p. 495, doi. 10.1007/s12094-021-02703-9

By:

Guillem Porta, Vicente;
Camps, Carlos;
Climent Durán, Miguel Ángel;
Gallardo, Enrique;
González del Alba, Aránzazu;
Lázaro-Quintela, Martín;
Méndez Vidal, María José;
Pinto Marín, Álvaro;
Puente, Javier;
Antón-Rodríguez, Cristina;
Caballero-Martínez, Fernando;
Campos-Lucas, Francisco J.;
Lugo, Ilse;
Rogado, Álvaro;
Durán, Ignacio

Publication type:

Article